Anthracycline cardiac dysfunction equivalence ratios

Cancer therapy-related cardiac dysfunction risk equivalence ratios for anthracycline and anthraquinone agents are needed to guide and optimize long-term follow-up in children treated with these agents. We have developed recommendations on cancer therapy-related cardiac dysfunction equivalence ratios for doxorubicin, daunorubicin, epirubicin, idarubicin, and mitoxantrone after childhood cancer treatment.

Recommendations for anthracycline and anthraquinone cardiac dysfunction equivalence ratios after childhood cancer